Skip to main content

Table 1 Patient and tumor characteristics treated with SOX+B-mab or SOX+C-mab

From: Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study)

Characteristics SOX+B-mab
(n = 22)
SOX+C-mab
(n = 23)
Total
(n = 45)
Age, median (range), year 67 (49–79) 66 (40–79) 66 (40–79)
Sex
 Male 14 (66.7) 15 (65.2) 29 (64.4)
 Female 8 (33.3) 8 (34.8) 16 (35.6)
ECOG performance status
 0 17 (71.4) 18 (78.3) 35 (77.8)
 1 4 (23.8) 4 (17.4) 8 (17.8)
 2 1 (4.8) 1 (4.3) 2 (4.4)
TNM at study entry
 T T3 / T4a / T4b 10 / 11 / 1 14 / 4 / 5 24 / 15 / 6
 N N0 / N1/ N2a / N2b 5 / 7 / 7 / 3 5 / 6 / 9 / 3 10 / 13 / 16 / 6
 M M1a / M1b / M1c 12 / 8 / 2 8 / 10 / 5 20 / 18 / 7
Primary tumor resected at study entry
 Yes 17 (77.3) 14 (60.9) 31 (68.9)
 No 5 (22.7) 9 (39.1) 14 (31.1)
Metastatic sites at start of treatment
 Liver only 5 (22.7) 4 (17.4) 9 (20.0)
 Liver 14 (63.6) 15 (65.2) 29 (64.4)
 Lung 4 (18.2) 8 (34.8) 12 (26.7)
 Lymph nodes 15 (68.2) 15 (65.2) 30 (66.7)
 Peritoneum 3 (13.6) 5 (21.7) 8 (17.8)
 Others 1 (4.5) 3 (13.0) 4 (8.9)
Colorectal cancer location at diagnosis
 Left 17 (77.3) 19 (82.6) 36 (81.4)
 Right 5 (21.7) 4 (17.4) 9 (18.6)
  1. ECOG Eastern Cooperative Oncology Group